RespireRx Pharmaceuticals Inc. Announces a Department of Defense Award to Fund a Phase 2 Clinical Study to Determine the Safety and Efficacy of CX1739, its Lead AMPAkine, to Improve Bladder Function in Patients with Spinal Cord Injury
RespireRx Pharmaceuticals Inc. Announces Positive Results from Phase 2B PACE Study Conducted by the University of Illinois Dronabinol Reduces Symptoms of Obstructive Sleep Apnea
RespireRx Pharmaceuticals Inc. Announces Data for CX1739 Clinical Study in Opioid Induced Respiratory Depression
Noble Mineral highlights Successful Exploration Results announced by Canada Nickel, including Highest Grade to Date at Mann West
CHARBONE Hydrogen and ABB Sign Agreement to Advance North American Green Hydrogen Production Facilities
